Skip to main content
Have a personal or library account? Click to login
Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies Cover

Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies

Radiology and Oncology
Volume 47 (2013): Issue 1 (March 2013)
By: ,  ,  ,  ,  ,  ,   and    
Open Access
|Feb 2013
References

References

  1. 1. Matos E, Cufer T. Adjuvant treatment of breast cancer with transtuzumab.2007; 41: 115-22.
    Open DOISearch in Google Scholar
  2. 2. Rajer M, Majdic E. Locoregional control and survival after conserving therapy.2006;23-8.
    Search in Google Scholar
  3. 3. Kaufmann M, Hortobagy GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.2006;1940-9.
    Open DOISearch in Google Scholar
  4. 4. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.2006;1037-44.
    Open DOISearch in Google Scholar
  5. 5. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European cooperative trial in operable breast cancer.2009;2474-81.
    Open DOISearch in Google Scholar
  6. 6. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.2001;96-102.
    Open DOISearch in Google Scholar
  7. 7. von Minckwitz G, Blohmer JU, Raab G, Loehr A, Gerber B, Heinrich G, et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.2005;56-63.
    Open DOISearch in Google Scholar
  8. 8. Alvarez RH, Hortobagyi GN. Primary systemic therapy for operable breast cancer patients: the need for the new generation of trial design.2010;701-5.
    Open DOISearch in Google Scholar
  9. 9. Untch M, von Minkwitz G. Advances in neoadjuvant (primary) systemic therapy with cytotoxic agents.2009;203-10.
    Open DOISearch in Google Scholar
  10. 10. von Minkwitz G, Raab G, Caputo A, Schuette M, Hilfrich J, Blohmer JU, et al. Doxorubicin with Cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.2005;2676-85.
    Open DOISearch in Google Scholar
  11. 11. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.2009;736-50.
    Open DOISearch in Google Scholar
  12. 12. Kim SI, Sohn J, Koo JS, Park SH, Park HS, Park BW. Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.2010;324-30.
    Open DOISearch in Google Scholar
  13. 13. Lips EH, Mulder L, de Ronde JJ, Mandjes IAM, Vincent A, Vrancken Peeters MT, et al. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.2012;827-36.
    Open DOISearch in Google Scholar
  14. 14. von Minkwitz G, Untch M, Nuesch E, Loibi S, Kaufmann M, Kuemmel S, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.2011;145-56.
    Open DOISearch in Google Scholar
  15. 15. Lombardi D, Scalone S, Crivellari D, Magri MD, La Mura N, Miolo G, et al. Epirubicin and docetaxel as neoadjuvant treatment of locally advanced breast cancer: a phase II study.2010;229-33.
    Open DOISearch in Google Scholar
  16. 16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors.2000;205-16.
    Open DOISearch in Google Scholar
  17. 17. Common Toxicity Criteria, Version 2.0. National Institutes of Health, National Cancer Institute. Available. http://www.eortc.be/services/doc/ctc/ ctcv20_4-30-992.pdf
    Search in Google Scholar
  18. 18. Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Science Publications; 1987.
    Search in Google Scholar
  19. 19. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau S-W, Broglio K, Theriault RL, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.2005;41-8.
    Open DOISearch in Google Scholar
  20. 20. Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, et al. Sequential preoperative and postoperative docetaxel added to preoperative Doxorubicin plus Cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Prroject Protocol B-27.2006;2019-27.
    Open DOISearch in Google Scholar
  21. 21. Chia YH, Ellis MJ, Ma CX. Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.2010;759-64.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/raon-2013-0012 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 57 - 62
Published on: Feb 1, 2013
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
breast cancer,
docetaxel,
epirubicin,
neoadjuvant chemotherapy
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2013 Alessandro Tuzi, Davide Lombardi, Diana Crivellari, Loredana Militello, Tiziana Perin, Manuela La Grassa, Samuele Massarut, Andrea Veronesi, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 47 (2013): Issue 1 (March 2013)
Previous article
Next article